KAI (kī)
Pharmaceuticals is a biology-based, product-driven biopharmaceutical company
developing a new class of therapeutics that selectively target enzymes within
the protein kinase C (PKC) family. KAI has leveraged this broad PKC platform to
rapidly advance product candidates into human clinical trials with an initial
clinical focus in acute
cardiovascular disease, metabolic
bone disease and pain .
Each compound in KAI’s pipeline
represents a novel treatment approach in its therapeutic area, utilizing
first-in-class technology to target well-validated disease
mechanisms.
Our lead product, KAI-9803,
is designed to reduce injury associated with ischemia and reperfusion in the
settings of acute myocardial infarction (AMI), stroke, renal transplant and
other ischemic conditions. In a phase 1/2 clinical study in patients undergoing
balloon angioplasty for the treatment of AMI, patients receiving KAI-9803
experienced less damage to the heart muscle compared to patients receiving a
placebo. The FDA has granted KAI-9803 Fast Track designation due to the
significant unmet medical need for this indication. KAI-1455 ,
our development candidate for secondary hyperparathyroidism (SHPT) completed a
phase 1 trial in 2007 and KAI-1678 , our development
candidate for inflammatory and neuropathic pain, will enter a phase 1 clinical
trial in mid-2008.
|
|
